Frontlight ResearchEarly access
CompletedNo phase
Jewel Electrophysiology (EP) Lab Study
Key facts
- Who runs it
- Element Science, Inc.
- Where
- Czechia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 18 people enrolled
- Started
- 27 Nov 2018
- Ended
- 17 Apr 2024
- Type of study
- Interventional
- Treatments tested
- Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
- Record updated
- 27 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Subjects of both genders of at least 18 years of age
- Subjects who are scheduled for a standard EP clinical procedure where fast VT or VF may spontaneously occur or may be induced
Who cannot take part
- Subjects who have been diagnosed with heart failure (Class IV) or experienced an acute heart failure exacerbation within the previous 30 days
- Subjects who are participating in an investigational study of a drug, biologic, or device not currently approved for marketing
- Subjects who exhibit unstable angina
- Subjects who are allergic to or have had a known adverse reaction to medical adhesives
- Subjects who have active skin breakdown, erythema, or other signs of infection in the pectoral or torso regions where the study device is applied
- Any condition that an Investigator believes would interfere with the intent of the study or is not in the best interest of the patient
- Subjects who exhibit a left ventricular ejection fraction (LVEF) less than 20% (as assessed by techniques such as echocardiography, magnetic resonance imaging, or radionuclide angiography) within the last 6 months
- Subjects who may require sterile access to the right upper pectoral or lower left torso regions during the planned EP procedure
- Subjects who have taken amiodarone in the past 3 months
- Subjects with an existing unipolar pacemaker
- Subjects with atrial fibrillation with contraindication to anticoagulation or improper anticoagulation management
- Subjects with a lower abdomen circumference of less than 68.5 cm or greater than 142 cm
- Females who are pregnant or breastfeeding, or planning to be pregnant in the next 12 months
- Subjects who cannot provide or have diminished capacity to provide informed consent
- Any patient that according to the Declaration of Helsinki is unsuitable for enrollment
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Single arm open label evaluation of the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) defibrillation waveform in adult cardiac patients.
The group in the trial
- TreatmentTreatment being tested
Safety and Effectiveness
Treatment: Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- First human safety and effectiveness study of defibrillation with a novel patch wearable cardioverter-defibrillator.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2024
- Record updated
- 27 April 2026